Fifteen analysts who offered stock ratings for Neurocrine Biosciences in the last three months forecast the average price in 12 months at 12100 with a high forecast of 14500 and a low forecast of 9000. It discovers develops and intends to commercialize drugs for the treatment of neurological and endocrine related. Working At Neurocrine Biosciences Glassdoor The institutional investor owned 1625 shares of the companys stock after purchasing an additional 195 shares during the quarter. Neurocrine biosciences inc . Is a neuroscience-focused biopharmaceutical company. Neurocrine Biosciences Inc. It discovers develops and intends to commercialize drugs for the treatment of neurological and endocrine related. FDA approves fibroid-associated menstruation therapy AbbVie Inc. IFP Advisors Incs holdings in. Is a neuroscience-focused biopharmaceutical company. IFP Advisors Inc boosted its holdings in Neurocrine Biosciences Inc. NYSEABBV and Neurocrine Biosciences IncStaff Wr...